Opioids: Intellipharmaceutics' Pursuit Of IV-Only Deterrence Claim May Backfire

Jul 25 2017

• By Sue Sutter

Listen to this article

US FDA advisory committee may not be comfortable with intravenous abuse-deterrence labeling for Rexista (oxycodone extended-release) when the sponsor has not assessed the impact on other routes of abuse purportedly targeted by the formulation.

Intellipharmaceutics International Inc. decision to pursue only an intravenous abuse-deterrence labeling for Rexista (oxycodone extended-release) could prove problematic for a US FDA advisory committee and has the potential to raise the same types of concerns about excipients and shifting routes of abuse that led the agency to seek withdrawal of Endo Pharmaceuticals Inc.'s Opana ER.

FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees will convene July 26 to consider...

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says
Sep 11 2024
• By Sue Sutter
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Recent And Upcoming FDA Advisory Committee Meetings
Aug 23 2024
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
EU Filings Tracker TEST
Aug 22 2024
New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.
US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks
Aug 21 2024
• By Sue Sutter
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says
Sep 11 2024
• By Sue Sutter
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Global Pharma Guidance Tracker – August 2024
Sep 09 2024
• By Vibha Sharma
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Recent And Upcoming FDA Advisory Committee Meetings
Aug 23 2024
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.